What is the youngest age for Purified Protein Derivative (PPD) testing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Youngest Age for PPD Testing

PPD (tuberculin skin testing) can be performed starting at 3 months of age in high-risk populations, particularly HIV-infected children, with annual testing recommended thereafter. 1

Age-Based Recommendations for PPD Testing

High-Risk Pediatric Populations

  • For HIV-infected children, annual Mantoux tuberculin skin testing should begin at age 3-12 months using intradermally injected 5 TU purified protein derivative (PPD). 1

  • Children younger than 4 years of age are considered at increased risk for tuberculosis and warrant PPD testing with a positive cutoff of ≥10 mm induration. 1, 2

  • All infants and children younger than 4 years with ≥10 mm skin test induration are classified as recent converters and candidates for preventive therapy. 2

Special Circumstances in Newborns

  • For newborns exposed to mothers with infectious tuberculosis, tuberculin skin testing should be performed at 3 months after starting isoniazid prophylaxis, not at birth. 3

  • Tuberculin-negative (<5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months should receive preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. 2

Critical Clinical Considerations

Why Testing Below 3 Months Is Problematic

  • False-negative reactions occur more frequently in infants and young children, particularly early (<6-8 weeks) after infection, due to immature cellular immune responses. 1

  • Children aged <2 years or those with HIV infection are more likely to have negative skin tests even when infected with tuberculosis. 1

Interpretation in Young Children

  • Among children and adults with HIV infection, >5 mm of induration is considered a positive (diagnostic) reaction. 1

  • For children younger than 4 years who are contacts of TB cases or have other risk factors, >10 mm induration is considered positive. 1

Common Pitfalls to Avoid

  • Do not use multiple puncture TB skin tests (e.g., Tine tests) in any age group—only the Mantoux method with intradermal injection is recommended. 1

  • Do not delay PPD testing in exposed infants while waiting for symptoms to develop—the 3-month checkpoint after exposure is critical for detecting infection. 3

  • Do not give BCG vaccination before completing the 3-month assessment in exposed infants, as this can complicate interpretation of subsequent TST results. 3

  • Do not assume a negative PPD rules out tuberculosis disease in young children, as approximately 10% of children without HIV infection but with culture-positive TB disease do not react initially to TST. 1

Practical Algorithm for Young Children

For routine screening in high-risk children:

  • Begin annual PPD testing at 3-12 months of age in HIV-infected children 1
  • Test children <4 years with known TB exposure immediately, regardless of age 1, 2

For newborns with maternal TB exposure:

  • Start isoniazid prophylaxis immediately (do not wait for testing) 3
  • Perform first TST at 3 months after exposure/prophylaxis initiation 3
  • If TST converts to positive, complete 6 months of prophylaxis 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Newborns Exposed to Mothers with Tuberculosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.